Page last updated: 2024-08-24

triazoles and raltegravir potassium

triazoles has been researched along with raltegravir potassium in 64 studies

Research

Studies (64)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	20 (31.25)	29.6817
2010's	43 (67.19)	24.3611
2020's	1 (1.56)	2.80

Authors

Authors	Studies
Boffito, M; Mallon, PW; Winston, A	1
Temesgen, Z	1
Stephenson, J	1
Laurence, J	1
Boyle, BA; Cohen, CJ; Elion, R; Frank, I; Moyle, GJ; Sax, P	1
Al-Mawsawi, LQ; Dayam, R; Neamati, N	1
Taéron, C	1
Barber, T; Hughes, A; Nelson, M	1
Hussar, DA	1
Barros Aguado, C; Morales Conejo, M; Moreno Cuerda, VJ; Rubio García, R	1
Boyle, B; Cohen, C; DeJesus, E; Elion, R; Frank, I; Moyle, G; Sax, P	1
Ascenzi, P; Bellagamba, R; Narciso, P; Nicastri, E; Notari, S; Pucillo, LP; Tempestilli, M; Tommasi, C	1
Barreca, ML; Chimirri, A; De Luca, L; Iraci, N	1
Arribas, JR	1
Fätkenheuer, G; Kümmerle, T; Lehmann, C; Meuer, K	1
Cohen, AF; Dubois, EA	1
Andrews, E; Crownover, P; Damle, B; Fang, J; Glue, P; Tressler, R	1
Armstrong-James, D; Ferns, B; Nelson, M; Pillay, D; Scourfield, A; Smit, E; Stebbing, J	1
Baroncelli, S; Cicalini, S; Cusato, M; Floridia, M; Francisci, D; Galluzzo, C; Ladisa, N; Preziosi, R; Regazzi, M; Tommasi, C; Villani, P; Vullo, V; Weimer, LE	1
Ferrando-Martínez, S; García-Pergañeda, A; Genebat, M; González-Serna, A; Leal, M; Méndez, G; Pulido, I; Romero-Sánchez, MC; Ruiz-Mateos, E	1
Akkina, R; Habu, Y; Ndolo, T; Neff, CP; Tandon, A	1
Bigoloni, A; Castagna, A; Cossarini, F; Della Torre, L; Galli, A; Galli, L; Lazzarin, A; Nicola, G; Nozza, S; Pogliaghi, M; Salpietro, S; Tambussi, G	1
Zhang, XQ	1
Büchel, G; Haefeli, WE; Herzog, M; Jödicke, L; Weiss, J; Zembruski, NC	1
Bonora, S; Calcagno, A; Castagna, A; D'Avolio, A; Di Perri, G; Gonzalez de Requena, D; Lazzarin, A; Nozza, S	1
Banerjee, S; Davis, J; Labadie, RR; Langdon, G; Layton, G; Ndongo, MN; Vourvahis, M	1
Back, DJ; Else, LJ; Khoo, SH; Taylor, S	1
Boyd, SD; McLaughlin, M; Morse, CG; Pau, AK; Penzak, SR	1
Katanaga, H	1
Colby-Germinario, SP; Donahue, DA; Kramer, VG; Oliveira, M; Schader, SM; Singhroy, DN; Sloan, RD; Tressler, R; Wainberg, MA	1
Acosta, EP; Barreca, ML; Chirullo, B; Collins, M; Della Corte, A; Greenhouse, J; Iraci, N; Lewis, MG; Norelli, S; Savarino, A; Shytaj, IL; Yalley-Ogunro, J	1
Bigoloni, A; Carini, E; Castagna, A; Cossarini, F; Galli, L; Gianotti, N; Lazzarin, A; Nozza, S; Piatti, P; Salpietro, S; Spagnuolo, V; Vinci, C	1
Abad Fernández, M; Díaz, L; Dronda, F; Gutiérrez, C; Hernández-Novoa, B; Madrid, N; Moreno, S; Muñoz-Fernández, MÁ; Serrano-Villar, S; Vallejo, A; Zamora, J	1
Cardoso, SW; Grinsztejn, B; Guimarães, ML; Morgado, MG; Passaes, CP; Pilotto, JH; Veloso, V	1
Boonchawalit, S; Harada, S; Matsushita, S; Yamaguchi, A; Yoshimura, K; Yusa, K	1
Antoniou, T; Brunetta, J; Halpenny, R; Hasan, S; Kovacs, C; La Porte, C; Loutfy, MR; Smith, G	1
Baraki, B; Benko, E; Brumme, ZL; Danroth, R; Huibner, S; Kaul, R; Kovacs, C; Le, AQ; Mazzulli, T; Osborne, BJ; Porte, Cl; Sheth, PM; Yi, TJ	1
Lacombe, K; Surgers, L	1
Bicudo, EL; Cassoli, LM; da Eira, M; de Andrade Neto, JL; Furtado, J; Leite, OH; Lewi, DS; Lima, MP; Lopes, MI; Machado, AA; Madruga, JV; Miranda, AF; Netto, EM; Pedro, Rde J; Portsmouth, S; Santini-Oliveira, M; Santos, BR; Tupinambas, U; Wajsbrot, DB	1
Binet, L; Djerada, Z; Feliu, C; Gozalo, C; Lamiable, D; Marty, H; Millart, H; Robinet, A; Tournois, C; Vautier, D	1
Degli Antoni, A; Ferrari, C; Fragola, V; Manfredi, R; Weimer, LE	1
Ballestero, M; Blanco, J; Boix, J; Buzon, MJ; Clotet, B; Esteve, A; Gatell, JM; Llibre, JM; Manzardo, C; Martinez-Picado, J; Massanella, M; Miró, JM; Ouchi, D; Puertas, MC	1
Abad-Fernández, M; Díaz, L; Dronda, F; Gutiérrez, C; Hernández-Novoa, B; Madrid, N; Moreno, A; Moreno, S; Muñoz-Fernández, MA; Serrano-Villar, S; Vallejo, A; Zamora, J	1
Caskey, M; Evering, TH; Garmon, D; La Mar, M; Markowitz, M; Mohri, H; Palmer, S; Prada, N; Rodriguez, K; Sahi, V	1
Bigoloni, A; Bonora, S; Calcagno, A; Carbone, A; Castagna, A; D'Avolio, A; Galli, L; Lazzarin, A; Nozza, S; Pignataro, AR; Ripa, M	1
Assoumou, L; Chablais, L; Costagliola, D; Duvivier, C; Katlama, C; Kolta, S; Marcelin, AG; Mercié, P; Peytavin, G; Pialoux, G; Simon, A; Soulié, C; Valantin, MA	1
Bigoloni, A; Carbone, A; Castagna, A; Chiappetta, S; Galli, L; Gianotti, N; Lazzarin, A; Nozza, S; Ripa, M; Spagnuolo, V; Tambussi, G	1
Assoumou, L; Autran, B; Campillo-Gimenez, L; Capeau, J; Costagliola, D; Guihot, A; Katlama, C; Marcelin, AG; Pajanirassa, P; Soulié, C; Valantin, MA; Villemonteix, J	1
Assoumou, L; Calvez, V; Chas, J; Duvivier, C; Katlama, C; Lê, MP; Marcelin, AG; Peytavin, G; Ponscarme, D; Soulié, C; Valantin, MA	1
Assoumou, L; Caby, F; Calvez, V; Canestri, A; Costagliola, D; Darty, M; Donati, F; Katlama, C; Marcelin, AG; Peytavin, G; Rodriguez, C; Sayon, S; Schneider, L; Soulié, C; Valantin, MA	1
Albanese, A; Asmuth, DM; Chun, TW; Deeks, SG; Kashuba, AD; Landay, A; Ma, ZM; Mann, S; Miller, CJ; Moreno, S; Pollard, RB; Sainz, T; Serrano-Villar, S; Siewe, B; Sinclair, E; Somasunderam, A; Troia-Cancio, P; Utay, NS; Wook-Chun, T; Yotter, T	1
Allmon, A; Cottrell, ML; Dellon, ES; Hudgens, MG; Kashuba, AD; Madanick, RD; Malone, S; Mollan, KR; Patterson, KB; Prince, HM; Shaheen, NJ; Sykes, C; White, N	1
Blakney, AK; Jiang, Y; Whittington, D; Woodrow, KA	1
Brochier, C; Cottalorda-Dufayard, J; Cotte, L; Dellamonica, P; Durant, J; Gagnieu, MC; Gatey, C; Izopet, J; Jacomet, C; Lucht, F; Pradat, P; Raffi, F; Trabaud, MA; Vassallo, M	1
Marzinke, MA; Parsons, TL	1
Benko, E; Huibner, S; Kandel, G; Kaul, R; Kim, CJ; Kovacs, C; Ostrowski, M; Rousseau, R; Shahabi, K	1
Emanuel, K; Fox, HS; Lamberty, BG; Morsey, B; Stauch, KL	1
Belarbi, L; Chaix, ML; Dulioust, E; Duvivier, C; Ghosn, J; Launay, O; Lê, MP; Mahjoub, N; Peytavin, G; Salmon, D; Viard, JP	1
Asmuth, DM; Chun, TW; Garcia, JC; Kashuba, AD; Landay, A; Ma, ZM; Mann, S; Miller, CJ; Pollard, RB; Sainz, T; Serrano-Villar, S; Thompson, CG; Troia-Cancio, P; Utay, NS	1
Cottrell, ML; Imaz, A; Kashuba, AD; Podzamczer, D; Schauer, AP; Sykes, C	1

Reviews

7 review(s) available for triazoles and raltegravir potassium

Article	Year
The clinical pharmacology of antiretrovirals in development. Expert opinion on drug metabolism & toxicology, 2006, Volume: 2, Issue:3 Topics: Animals; Anti-Retroviral Agents; CCR5 Receptor Antagonists; Clinical Trials as Topic; Cyclohexanes; Darunavir; Drug Evaluation, Preclinical; Drug Interactions; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; HIV-1; Humans; Maraviroc; Nitriles; Organic Chemicals; Protease Inhibitors; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Receptors, CCR5; Reverse Transcriptase Inhibitors; Sulfonamides; Triazoles	2006
New treatment options for HIV salvage patients: an overview of second generation PIs, NNRTIs, integrase inhibitors and CCR5 antagonists. The Journal of infection, 2008, Volume: 57, Issue:1 Topics: Anti-HIV Agents; CCR5 Receptor Antagonists; Clinical Trials as Topic; Cyclohexanes; Darunavir; HIV Fusion Inhibitors; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; HIV-1; Humans; Maraviroc; Nitriles; Pyridazines; Pyridines; Pyrimidines; Pyrones; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Salvage Therapy; Sulfonamides; Treatment Outcome; Triazoles	2008
[New CCR5 inhibitor antiretroviral drugs and integrase inhibitors]. Revista clinica espanola, 2008, Volume: 208, Issue:9 Topics: CCR5 Receptor Antagonists; Cyclohexanes; HIV Fusion Inhibitors; Humans; Integrase Inhibitors; Maraviroc; Pyrrolidinones; Raltegravir Potassium; Triazoles	2008
[Role of the new molecules in antiretroviral therapy. Position of raltegravir]. Enfermedades infecciosas y microbiologia clinica, 2008, Volume: 26 Suppl 12 Topics: Anti-HIV Agents; CCR5 Receptor Antagonists; Clinical Trials as Topic; Cyclohexanes; Darunavir; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Enfuvirtide; Forecasting; HIV Envelope Protein gp41; HIV Fusion Inhibitors; HIV Infections; HIV Integrase Inhibitors; Humans; Maraviroc; Nitriles; Peptide Fragments; Pyridazines; Pyridines; Pyrimidines; Pyrones; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Sulfonamides; Triazoles	2008
[The newest developments in anti-HIV-1 drugs]. Yao xue xue bao = Acta pharmaceutica Sinica, 2010, Volume: 45, Issue:2 Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cyclohexanes; Drug Resistance, Viral; Enfuvirtide; HIV Envelope Protein gp41; HIV Fusion Inhibitors; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; HIV Reverse Transcriptase; HIV-1; Humans; Maraviroc; Molecular Structure; Peptide Fragments; Pyrrolidinones; Raltegravir Potassium; Saquinavir; Triazoles; Virus Replication; Zidovudine	2010
Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the fetal compartment (placenta and amniotic fluid). Antiviral therapy, 2011, Volume: 16, Issue:8 Topics: Adenine; Adult; Amniotic Fluid; Anti-HIV Agents; Cyclohexanes; Enfuvirtide; Female; Fetal Blood; Fetus; HIV Envelope Protein gp41; HIV Fusion Inhibitors; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Maraviroc; Nevirapine; Organophosphonates; Peptide Fragments; Placenta; Pregnancy; Pregnancy Complications, Infectious; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Tenofovir; Triazoles; Viral Load; Zidovudine	2011
Hepatoxicity of new antiretrovirals: a systematic review. Clinics and research in hepatology and gastroenterology, 2013, Volume: 37, Issue:2 Topics: Anti-Retroviral Agents; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Cyclohexanes; Darunavir; Heterocyclic Compounds, 3-Ring; Humans; Maraviroc; Nitriles; Oxazines; Piperazines; Pyridazines; Pyridones; Pyrimidines; Pyrrolidinones; Quinolones; Raltegravir Potassium; Rilpivirine; Sulfonamides; Triazoles	2013

Trials

15 trial(s) available for triazoles and raltegravir potassium

Article	Year
Raltegravir plasma concentrations in treatment-experienced patients receiving salvage regimens based on raltegravir with and without maraviroc coadministration. The Annals of pharmacotherapy, 2010, Volume: 44, Issue:5 Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cohort Studies; Cyclohexanes; Drug Administration Schedule; Drug Interactions; HIV Infections; Humans; Male; Maraviroc; Middle Aged; Pyrrolidinones; Raltegravir Potassium; Salvage Therapy; Triazoles; Young Adult	2010
Durability and safety of a novel salvage therapy in R5-tropic HIV-infected patients: maraviroc, raltegravir, etravirine. Journal of acquired immune deficiency syndromes (1999), 2011, Volume: 56, Issue:4 Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cyclohexanes; Female; HIV Infections; Humans; Male; Maraviroc; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; RNA, Viral; Salvage Therapy; Treatment Outcome; Triazoles; Viral Load	2011
Pharmacokinetic effects of coadministration of lersivirine with raltegravir or maraviroc in healthy subjects. Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:2 Topics: Adolescent; Adult; Anti-HIV Agents; Cross-Over Studies; Cyclohexanes; Drug Interactions; Drug Therapy, Combination; Female; HIV Fusion Inhibitors; HIV Integrase Inhibitors; Humans; Male; Maraviroc; Middle Aged; Nitriles; Pyrazoles; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Treatment Outcome; Triazoles; Young Adult	2012
Safety and immunovirologic outcomes with maraviroc combination regimens in patients with a history of past treatment failures and virologic resistance in Brazil: an open-label, multicenter phase 3b study. AIDS research and human retroviruses, 2013, Volume: 29, Issue:9 Topics: Adult; Anti-HIV Agents; Brazil; CCR5 Receptor Antagonists; CD4 Lymphocyte Count; Cyclohexanes; Darunavir; Drug Therapy, Combination; Female; HIV Fusion Inhibitors; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Maraviroc; Middle Aged; Protease Inhibitors; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Sulfonamides; Treatment Failure; Triazoles; Viral Load; Young Adult	2013
Intensification of a raltegravir-based regimen with maraviroc in early HIV-1 infection. AIDS (London, England), 2014, Jan-28, Volume: 28, Issue:3 Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cyclohexanes; DNA, Viral; Female; HIV Infections; HIV-1; Humans; Male; Maraviroc; Prospective Studies; Pyrrolidinones; Raltegravir Potassium; RNA, Viral; Treatment Outcome; Triazoles; Viral Load	2014
Dynamics of the HIV-1 latent reservoir after discontinuation of the intensification of antiretroviral treatment: results of two clinical trials. AIDS (London, England), 2013, Aug-24, Volume: 27, Issue:13 Topics: Adult; Anti-Retroviral Agents; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cyclohexanes; Female; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; Pilot Projects; Pyrrolidinones; Raltegravir Potassium; Triazoles; Virus Latency	2013
A randomized open-label study of 3- versus 5-drug combination antiretroviral therapy in newly HIV-1-infected individuals. Journal of acquired immune deficiency syndromes (1999), 2014, Jun-01, Volume: 66, Issue:2 Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cyclohexanes; DNA, Viral; Drug Combinations; Endpoint Determination; HIV Infections; Humans; Longitudinal Studies; Male; Maraviroc; Middle Aged; Pyrrolidinones; Raltegravir Potassium; RNA, Viral; Triazoles; Viral Load; Viremia	2014
Maraviroc plus raltegravir failed to maintain virological suppression in HIV-infected patients with lipohypertrophy: results from the ROCnRAL ANRS 157 study. The Journal of antimicrobial chemotherapy, 2014, Volume: 69, Issue:6 Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cyclohexanes; Female; HIV Infections; HIV-1; Humans; Lipodystrophy; Male; Maraviroc; Middle Aged; Pyrrolidinones; Raltegravir Potassium; Risk Factors; Treatment Failure; Triazoles; Viral Load	2014
Four-year outcome of a PI and NRTI-sparing salvage regimen: maraviroc, raltegravir, etravirine. The new microbiologica, 2014, Volume: 37, Issue:2 Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Blood Cell Count; Cyclohexanes; Drug Therapy, Combination; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Maraviroc; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Treatment Outcome; Triazoles	2014
Plasma concentrations of maraviroc and raltegravir after dual therapy in patients with long-term suppressed viraemia: ROCnRAL ANRS 157 study. The Journal of antimicrobial chemotherapy, 2015, Volume: 70, Issue:8 Topics: Anti-HIV Agents; Chromatography, Liquid; Cyclohexanes; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Maraviroc; Middle Aged; Plasma; Raltegravir Potassium; Tandem Mass Spectrometry; Triazoles	2015
Virological factors associated with outcome of dual maraviroc/raltegravir therapy (ANRS-157 trial). The Journal of antimicrobial chemotherapy, 2015, Volume: 70, Issue:12 Topics: Anti-HIV Agents; Cyclohexanes; HIV Infections; HIV-1; Maraviroc; Raltegravir Potassium; Risk Factors; Treatment Failure; Triazoles; Viral Load	2015
Effects of Combined CCR5/Integrase Inhibitors-Based Regimen on Mucosal Immunity in HIV-Infected Patients Naïve to Antiretroviral Therapy: A Pilot Randomized Trial. PLoS pathogens, 2016, Volume: 12, Issue:1 Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CCR5 Receptor Antagonists; Chromatography, High Pressure Liquid; Cyclohexanes; Cyclopropanes; Drug Combinations; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Enzyme-Linked Immunosorbent Assay; Female; Flow Cytometry; HIV Infections; HIV Integrase Inhibitors; Humans; Immunity, Mucosal; Lymphocyte Activation; Male; Maraviroc; Pilot Projects; Raltegravir Potassium; T-Lymphocyte Subsets; Triazoles	2016
Maraviroc/raltegravir simplification strategy following 6 months of quadruple therapy with tenofovir/emtricitabine/maraviroc/raltegravir in treatment-naive HIV patients. The Journal of antimicrobial chemotherapy, 2016, Volume: 71, Issue:11 Topics: Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cyclohexanes; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Maintenance Chemotherapy; Male; Maraviroc; Middle Aged; Raltegravir Potassium; Tenofovir; Treatment Outcome; Triazoles; Viral Load; Young Adult	2016
Impact of intensified antiretroviral therapy during early HIV infection on gut immunology and inflammatory blood biomarkers. AIDS (London, England), 2017, 07-17, Volume: 31, Issue:11 Topics: Adult; Anti-HIV Agents; Biomarkers; Canada; Cyclohexanes; Double-Blind Method; Drug Therapy, Combination; Fibrin Fibrinogen Degradation Products; Flow Cytometry; HIV Infections; Humans; Immunity, Mucosal; Inflammation; Intestinal Mucosa; Lymphocyte Activation; Male; Maraviroc; Middle Aged; Prospective Studies; Raltegravir Potassium; Th17 Cells; Treatment Outcome; Triazoles; Young Adult	2017
Tissue Pharmacologic and Virologic Determinants of Duodenal and Rectal Gastrointestinal-Associated Lymphoid Tissue Immune Reconstitution in HIV-Infected Patients Initiating Antiretroviral Therapy. The Journal of infectious diseases, 2017, 10-17, Volume: 216, Issue:7 Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclohexanes; Cyclopropanes; DNA, Viral; Duodenum; Female; HIV Infections; Humans; Lymphoid Tissue; Male; Maraviroc; Raltegravir Potassium; Rectum; RNA, Viral; Triazoles	2017

Other Studies

42 other study(ies) available for triazoles and raltegravir potassium

Article	Year
The latest in antiretroviral therapy. Drug news & perspectives, 2006, Volume: 19, Issue:8 Topics: Anti-HIV Agents; Anti-Retroviral Agents; Antibodies, Monoclonal; Antiretroviral Therapy, Highly Active; Clinical Trials as Topic; Cyclohexanes; Darunavir; Drugs, Investigational; HIV Infections; HIV-1; Humans; Maraviroc; Nitriles; Organic Chemicals; Piperazines; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Receptors, Chemokine; Sulfonamides; Treatment Outcome; Triazoles	2006
Researchers buoyed by novel HIV drugs: will expand drug arsenal against resistant virus. JAMA, 2007, Apr-11, Volume: 297, Issue:14 Topics: Anti-HIV Agents; Cyclohexanes; Drug Resistance, Viral; Drugs, Investigational; HIV Fusion Inhibitors; HIV Infections; HIV Integrase Inhibitors; Humans; Maraviroc; Organic Chemicals; Pyrrolidinones; Raltegravir Potassium; Triazoles	2007
Anti-HIV agents. New drugs, new hope, old lessons. TreatmentUpdate, 2007, Volume: 19, Issue:2 Topics: Alkynes; Anti-HIV Agents; Benzoxazines; CCR5 Receptor Antagonists; CD4 Lymphocyte Count; Cyclohexanes; Cyclopropanes; HIV Infections; HIV Integrase Inhibitors; Humans; Lipodystrophy; Maraviroc; Organic Chemicals; Pyrrolidinones; Raltegravir Potassium; Triazoles; Viral Load	2007
New drugs offer options. The AIDS reader, 2007, Volume: 17, Issue:4 Topics: Acquired Immunodeficiency Syndrome; Administration, Oral; Anti-HIV Agents; Clinical Trials as Topic; Cyclohexanes; Humans; Maraviroc; Organic Chemicals; Pyrrolidinones; Raltegravir Potassium; Triazoles	2007
Pivotal moments in HIV treatment: the 14th CROI. The AIDS reader, 2007, Volume: 17, Issue:5 Topics: Anti-Retroviral Agents; Clinical Trials as Topic; Congresses as Topic; Cyclohexanes; HIV Fusion Inhibitors; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Lopinavir; Maraviroc; Multicenter Studies as Topic; Organic Chemicals; Pyrimidinones; Pyrrolidinones; Raltegravir Potassium; Treatment Outcome; Triazoles; United States	2007
Advances in HIV therapeutics: the 14th CROI. The AIDS reader, 2007, Volume: 17, Issue:5 Topics: Acyclovir; Anti-HIV Agents; Circumcision, Male; Cyclohexanes; Dideoxynucleosides; Drug Interactions; Female; Hepatitis C; HIV Fusion Inhibitors; HIV Infections; Humans; Male; Maraviroc; Multicenter Studies as Topic; Nitriles; Organic Chemicals; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Randomized Controlled Trials as Topic; Triazoles	2007
Substituted 2-pyrrolinone inhibitors of HIV-1 integrase. Bioorganic & medicinal chemistry letters, 2007, Nov-15, Volume: 17, Issue:22 Topics: Furans; HIV Integrase; HIV Integrase Inhibitors; Humans; Molecular Structure; Organic Chemicals; Pyrroles; Pyrrolidinones; Quinolones; Raltegravir Potassium; Triazoles	2007
Two new drugs for HIV infection. The Medical letter on drugs and therapeutics, 2008, Jan-14, Volume: 50, Issue:1277 Topics: Administration, Oral; CCR5 Receptor Antagonists; Cyclohexanes; Drug Administration Schedule; Drug Costs; Drug Interactions; Drug Resistance, Viral; HIV Fusion Inhibitors; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Maraviroc; Organic Chemicals; Pyrrolidinones; Raltegravir Potassium; Treatment Outcome; Triazoles	2008
[New drugs for HIV infection]. Revue de l'infirmiere, 2008, Issue:138 Topics: Anti-HIV Agents; Contraindications; Cyclohexanes; Darunavir; Drug Monitoring; HIV Infections; Humans; Maraviroc; Nitriles; Organic Chemicals; Patient Education as Topic; Patient Selection; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Sulfonamides; Triazoles	2008
New drugs08, part 2. Nursing, 2008, Volume: 38, Issue:7 Topics: Acromegaly; Adult; Anti-Bacterial Agents; Anti-HIV Agents; Antineoplastic Agents; Biopterins; Carbapenems; Child; Child, Preschool; Cyclohexanes; Doripenem; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Epothilones; Humans; Infant; Maraviroc; Peptides, Cyclic; Pharmaceutical Preparations; Phenylketonurias; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Sirolimus; Somatostatin; Triazoles	2008
Antiretroviral treatment update from the 17th International AIDS Conference. The AIDS reader, 2008, Volume: 18, Issue:11 Topics: Anti-HIV Agents; Cardiovascular Diseases; CCR5 Receptor Antagonists; Cyclohexanes; HIV Infections; HIV Integrase Inhibitors; Humans; Maraviroc; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Triazoles	2008
Simultaneous determination of maraviroc and raltegravir in human plasma by HPLC-UV. IUBMB life, 2009, Volume: 61, Issue:4 Topics: Anti-HIV Agents; Chromatography, High Pressure Liquid; Cyclohexanes; Drug Monitoring; Humans; Maraviroc; Pyrrolidinones; Raltegravir Potassium; Triazoles; Ultraviolet Rays	2009
Induced-fit docking approach provides insight into the binding mode and mechanism of action of HIV-1 integrase inhibitors. ChemMedChem, 2009, Volume: 4, Issue:9 Topics: Acetoacetates; Anti-HIV Agents; Binding Sites; Computer Simulation; Drug Design; Furans; HIV Integrase; HIV Integrase Inhibitors; Humans; Mutation; Naphthyridines; Pyrroles; Pyrrolidinones; Quinolones; Raltegravir Potassium; Triazoles	2009
[New antiretroviral drug classes in HIV therapy]. MMW Fortschritte der Medizin, 2009, Apr-30, Volume: 151, Issue:18 Topics: Anti-HIV Agents; CCR5 Receptor Antagonists; Cyclohexanes; HIV Fusion Inhibitors; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Maraviroc; Piperazines; Pyrimidines; Pyrrolidinones; Quinolones; Raltegravir Potassium; Succinates; Triazoles; Triterpenes; Viral Load	2009
Maraviroc and raltegravir. British journal of clinical pharmacology, 2009, Volume: 68, Issue:5 Topics: Anti-HIV Agents; Cyclohexanes; Humans; Maraviroc; Pyrrolidinones; Raltegravir Potassium; Triazoles	2009
Assessment of the pharmacokinetics of co-administered maraviroc and raltegravir. British journal of clinical pharmacology, 2010, Volume: 69, Issue:1 Topics: Adult; Area Under Curve; Chromatography, Liquid; Cyclohexanes; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Female; HIV Fusion Inhibitors; HIV Infections; HIV Seronegativity; Humans; Male; Maraviroc; Middle Aged; Pyrrolidinones; Raltegravir Potassium; Tandem Mass Spectrometry; Triazoles	2010
Clinical outcome in resistant HIV-2 infection treated with raltegravir and maraviroc. Antiviral research, 2010, Volume: 86, Issue:2 Topics: Anti-HIV Agents; Cyclohexanes; Drug Resistance, Viral; Genotype; HIV Infections; HIV-2; Humans; Maraviroc; Pyrrolidinones; Raltegravir Potassium; RNA, Viral; Treatment Outcome; Triazoles	2010
Long-term immunovirogical effect and tolerability of a maraviroc-containing regimen in routine clinical practice. Current HIV research, 2010, Volume: 8, Issue:6 Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cyclohexanes; Female; Hepatitis C, Chronic; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Maraviroc; Middle Aged; Pyrrolidinones; Raltegravir Potassium; Retrospective Studies; Spain; Time; Triazoles; Viral Load	2010
Oral pre-exposure prophylaxis by anti-retrovirals raltegravir and maraviroc protects against HIV-1 vaginal transmission in a humanized mouse model. PloS one, 2010, Dec-21, Volume: 5, Issue:12 Topics: Administration, Oral; Animals; Anti-HIV Agents; Cyclohexanes; Disease Models, Animal; Female; Flow Cytometry; HIV Infections; HIV-1; Humans; Maraviroc; Mice; Mice, Transgenic; Post-Exposure Prophylaxis; Pyrrolidinones; Raltegravir Potassium; Triazoles; Vagina	2010
Potential of novel antiretrovirals to modulate expression and function of drug transporters in vitro. The Journal of antimicrobial chemotherapy, 2011, Volume: 66, Issue:4 Topics: Animals; Anti-Retroviral Agents; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Cell Survival; Cyclohexanes; Dogs; Gene Expression Profiling; Maraviroc; Piperazines; Pyrimidines; Pyrrolidinones; Quinolones; Raltegravir Potassium; Triazoles	2011
Pharmacokinetics of the raltegravir/maraviroc/etravirine combination. The Journal of antimicrobial chemotherapy, 2011, Volume: 66, Issue:8 Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cyclohexanes; Female; HIV Infections; Humans; Male; Maraviroc; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Salvage Therapy; Triazoles	2011
Impaired maraviroc and raltegravir clearance in a human immunodeficiency virus-infected patient with end-stage liver disease and renal impairment: a management dilemma. Pharmacotherapy, 2012, Volume: 32, Issue:1 Topics: Adult; Cyclohexanes; Disease Management; End Stage Liver Disease; Fatal Outcome; HIV Infections; Humans; Male; Maraviroc; Metabolic Clearance Rate; Pyrrolidinones; Raltegravir Potassium; Renal Insufficiency; Triazoles	2012
[Features and the method of application of a CCR5 antagonist, a new integrase inhibitor]. Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2009, Nov-10, Volume: 98, Issue:11 Topics: Anti-HIV Agents; CCR5 Receptor Antagonists; Cyclohexanes; HIV Integrase Inhibitors; Humans; Maraviroc; Pyrrolidinones; Raltegravir Potassium; Triazoles	2009
Maraviroc and other HIV-1 entry inhibitors exhibit a class-specific redistribution effect that results in increased extracellular viral load. Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:8 Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Benzylamines; Cell Line; Cyclams; Cyclohexanes; Cyclopropanes; DNA, Viral; Drug Resistance, Viral; Enfuvirtide; Heterocyclic Compounds; HIV Envelope Protein gp41; HIV Fusion Inhibitors; HIV Reverse Transcriptase; HIV-1; Humans; Maraviroc; Peptide Fragments; Pyrrolidinones; Raltegravir Potassium; Receptors, CCR5; Receptors, CXCR4; RNA, Viral; Triazoles; Viral Load; Virus Internalization	2012
A highly intensified ART regimen induces long-term viral suppression and restriction of the viral reservoir in a simian AIDS model. PLoS pathogens, 2012, Volume: 8, Issue:6 Topics: Adenine; Animals; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cyclohexanes; Darunavir; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Flow Cytometry; Fluorescent Antibody Technique; Macaca mulatta; Maraviroc; Organophosphonates; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Simian Acquired Immunodeficiency Syndrome; Sulfonamides; T-Lymphocyte Subsets; Tenofovir; Triazoles; Viral Load; Viremia	2012
Long-term glucose tolerance in highly experienced HIV-infected patients receiving nucleoside analogue-sparing regimens. AIDS (London, England), 2012, Sep-10, Volume: 26, Issue:14 Topics: Anti-HIV Agents; Blood Glucose; Cyclohexanes; Darunavir; Fasting; Glucose Tolerance Test; HIV Protease Inhibitors; HIV Seropositivity; HIV-1; Humans; Insulin; Insulin Resistance; Maraviroc; Nitriles; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Sulfonamides; Treatment Outcome; Triazoles; Viral Load	2012
The CD4/CD8 ratio in HIV-infected subjects is independently associated with T-cell activation despite long-term viral suppression. The Journal of infection, 2013, Volume: 66, Issue:1 Topics: Adult; Anti-Retroviral Agents; Bacterial Translocation; CD4-CD8 Ratio; Clinical Trials, Phase II as Topic; Cross-Sectional Studies; Cyclohexanes; Female; HIV Infections; Host-Pathogen Interactions; Humans; Lymphocyte Activation; Male; Maraviroc; Middle Aged; Multivariate Analysis; Pyrrolidinones; Raltegravir Potassium; Risk Factors; Statistics, Nonparametric; T-Lymphocytes; Triazoles; Viral Load	2013
Monitoring the emergence of resistance mutations in patients infected with HIV-1 under salvage therapy with raltegravir in Rio de Janeiro, Brazil: a follow-up study. Journal of medical virology, 2012, Volume: 84, Issue:12 Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Brazil; CD4 Lymphocyte Count; Cyclohexanes; Drug Resistance, Viral; Enfuvirtide; Follow-Up Studies; Genotyping Techniques; HIV Envelope Protein gp41; HIV Infections; HIV Integrase; HIV Protease; HIV Reverse Transcriptase; HIV-1; Humans; Maraviroc; Mutation; Peptide Fragments; Prospective Studies; Pyrrolidinones; Raltegravir Potassium; RNA, Viral; Salvage Therapy; Treatment Outcome; Triazoles; Viral Load; Virus Replication	2012
Impact of antiretroviral pressure on selection of primary human immunodeficiency virus type 1 envelope sequences in vitro. The Journal of general virology, 2013, Volume: 94, Issue:Pt 5 Topics: Amino Acid Sequence; Anti-HIV Agents; Base Sequence; Cyclohexanes; DNA, Viral; Genetic Variation; Genotype; Glycosylation; HIV Envelope Protein gp120; HIV Infections; HIV-1; Humans; Lamivudine; Maraviroc; Molecular Sequence Data; Phylogeny; Pyrrolidinones; Raltegravir Potassium; Receptors, CCR5; Receptors, CXCR4; Saquinavir; Sequence Analysis, DNA; Triazoles; Viral Tropism	2013
Pharmacokinetics of maraviroc, raltegravir, darunavir, and etravirine in the semen of HIV-infected men. Journal of acquired immune deficiency syndromes (1999), 2013, Feb-01, Volume: 62, Issue:2 Topics: Anti-HIV Agents; Area Under Curve; Cyclohexanes; Darunavir; HIV Infections; Humans; Male; Maraviroc; Middle Aged; Nitriles; Prospective Studies; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Semen; Sulfonamides; Triazoles	2013
Impact of antiretroviral therapy duration and intensification on isolated shedding of HIV-1 RNA in semen. The Journal of infectious diseases, 2013, Apr-15, Volume: 207, Issue:8 Topics: Amino Acid Sequence; Anti-Retroviral Agents; Base Sequence; Case-Control Studies; Cyclohexanes; HIV Infections; HIV-1; Humans; Incidence; Male; Maraviroc; Molecular Sequence Data; Prospective Studies; Pyrrolidinones; Raltegravir Potassium; RNA, Viral; Semen; Sequence Analysis, RNA; Sexual Behavior; Time Factors; Treatment Outcome; Triazoles; Viral Load; Viremia; Virus Shedding	2013
Validation of a fast method for quantitative analysis of elvitegravir, raltegravir, maraviroc, etravirine, tenofovir, boceprevir and 10 other antiretroviral agents in human plasma samples with a new UPLC-MS/MS technology. Journal of pharmaceutical and biomedical analysis, 2013, Volume: 86 Topics: Adenine; Anti-Retroviral Agents; Chromatography, High Pressure Liquid; Cyclohexanes; Humans; Maraviroc; Mass Spectrometry; Nitriles; Organophosphonates; Proline; Pyridazines; Pyrimidines; Pyrrolidinones; Quinolones; Raltegravir Potassium; Tandem Mass Spectrometry; Tenofovir; Time Factors; Triazoles	2013
A reduced grade of liver fibro-steatosis after raltegravir, maraviroc and fosamprenavir in an HIV/HCV co-infected patient with chronic hepatitis, cardiomyopathy, intolerance to nelfinavir and a marked increase of serum creatine phosphokinase levels probab The West Indian medical journal, 2012, Volume: 61, Issue:9 Topics: Adult; Carbamates; Cardiomyopathies; Chemical and Drug Induced Liver Injury; Creatine Kinase; Cyclohexanes; Drug Substitution; Drug Therapy, Combination; Fatty Liver; Furans; Hepatitis C, Chronic; HIV Fusion Inhibitors; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; Humans; Liver Cirrhosis; Male; Maraviroc; Organophosphates; Pyrrolidinones; Raltegravir Potassium; Sulfonamides; Triazoles	2012
Viral rebound after switch to maraviroc/raltegravir dual therapy in highly experienced and virologically suppressed patients with HIV-1 infection. The Journal of antimicrobial chemotherapy, 2014, Volume: 69, Issue:5 Topics: Cyclohexanes; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; Mutation, Missense; Pyrrolidinones; Raltegravir Potassium; Treatment Failure; Triazoles; Viral Load	2014
Switch to maraviroc/raltegravir dual therapy leads to an unfavorable immune profile with low-level HIV viremia. AIDS (London, England), 2015, Apr-24, Volume: 29, Issue:7 Topics: Anti-HIV Agents; CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cyclohexanes; Female; HIV Infections; Humans; Lymphocyte Activation; Male; Maraviroc; Middle Aged; Monocytes; Raltegravir Potassium; RNA, Viral; Treatment Outcome; Triazoles; Viral Load; Viremia	2015
Cervicovaginal and Rectal Fluid as a Surrogate Marker of Antiretroviral Tissue Concentration: Implications for Clinical Trial Design. Journal of acquired immune deficiency syndromes (1999), 2016, 08-15, Volume: 72, Issue:5 Topics: Adult; Anti-HIV Agents; Biomarkers; Body Fluids; Cervix Uteri; Clinical Trials as Topic; Cyclohexanes; Emtricitabine; Female; Healthy Volunteers; Humans; Maraviroc; Raltegravir Potassium; Rectum; Tenofovir; Triazoles; Vagina	2016
Simultaneous measurement of etravirine, maraviroc and raltegravir in pigtail macaque plasma, vaginal secretions and vaginal tissue using a LC-MS/MS assay. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2016, Jul-01, Volume: 1025 Topics: Animals; Anti-HIV Agents; Bodily Secretions; Chromatography, Liquid; Cyclohexanes; Female; Limit of Detection; Linear Models; Macaca nemestrina; Maraviroc; Nitriles; Pyridazines; Pyrimidines; Raltegravir Potassium; Reproducibility of Results; Tandem Mass Spectrometry; Triazoles; Vagina	2016
Prevention. Raltegravir, maraviroc show promise as PrEP drugs in studies. AIDS policy & law, 2016, Volume: 31, Issue:5 Topics: Cyclohexanes; HIV Infections; Humans; Maraviroc; Raltegravir Potassium; Triazoles	2016
Development and validation of a liquid chromatographic-tandem mass spectrometric method for the multiplexed quantification of etravirine, maraviroc, raltegravir, and rilpivirine in human plasma and tissue. Journal of pharmaceutical and biomedical analysis, 2016, Nov-30, Volume: 131 Topics: Chromatography, Liquid; Cyclohexanes; Humans; Maraviroc; Nitriles; Pyridazines; Pyrimidines; Raltegravir Potassium; Reproducibility of Results; Rilpivirine; Tandem Mass Spectrometry; Triazoles	2016
Central nervous system-penetrating antiretrovirals impair energetic reserve in striatal nerve terminals. Journal of neurovirology, 2017, Volume: 23, Issue:6 Topics: Adenosine Triphosphate; Alkynes; Animals; Anti-HIV Agents; Benzoxazines; Cerebral Cortex; Corpus Striatum; Cyclohexanes; Cyclopropanes; Darunavir; Dideoxynucleosides; Dose-Response Relationship, Drug; Emtricitabine; Lopinavir; Male; Maraviroc; Mitochondria; Neurons; Nevirapine; Oxidative Phosphorylation; Permeability; Presynaptic Terminals; Raltegravir Potassium; Rats; Rats, Long-Evans; Triazoles; Zidovudine	2017
Penetration and antiviral efficacy of total and unbound maraviroc, raltegravir and rilpivirine in both female and male genital fluids from HIV-positive patients receiving regimens containing these antiretrovirals. The Journal of antimicrobial chemotherapy, 2017, Nov-01, Volume: 72, Issue:11 Topics: Adult; Anti-HIV Agents; Body Fluids; Cervix Uteri; Cyclohexanes; Female; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; Prospective Studies; Raltegravir Potassium; Rilpivirine; Semen; Triazoles; Vagina; Viral Load	2017
Validation of an LC-MS/MS assay for the simultaneous determination of bictegravir, doravirine, and raltegravir in human plasma. Journal of pharmaceutical and biomedical analysis, 2022, Oct-25, Volume: 220 Topics: Amides; Chromatography, Liquid; Heterocyclic Compounds, 3-Ring; HIV Integrase Inhibitors; Humans; Piperazines; Pyridones; Raltegravir Potassium; Reproducibility of Results; Reverse Transcriptase Inhibitors; Tandem Mass Spectrometry; Triazoles	2022